MX2018013517A - Humanized anti-il-1r3 antibodies. - Google Patents
Humanized anti-il-1r3 antibodies.Info
- Publication number
- MX2018013517A MX2018013517A MX2018013517A MX2018013517A MX2018013517A MX 2018013517 A MX2018013517 A MX 2018013517A MX 2018013517 A MX2018013517 A MX 2018013517A MX 2018013517 A MX2018013517 A MX 2018013517A MX 2018013517 A MX2018013517 A MX 2018013517A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- antibody
- cancer
- pharmaceutical composition
- mediated disease
- Prior art date
Links
- 101000960952 Homo sapiens Interleukin-1 receptor accessory protein Proteins 0.000 abstract 5
- 102100039880 Interleukin-1 receptor accessory protein Human genes 0.000 abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present disclosure relates to humanized antibodies that specifically bind to IL-1R3 or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer IL-1R3 binding specificity. Said antibodies inhibit IL-1R3 induced NFkB activity. They also inhibit IL-1alpha, IL-1beta, IL-33, and/or IL-36 stimulated NFkB activity. The disclosure further relates to use of said humanized antibody in the treatment of an IL-1R3 mediated disease such as cancer. The disclosure finally encompasses a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention. The pharmaceutical composition can be used in treating a IL-1R3 mediated disease such as cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16168617.5A EP3241845A1 (en) | 2016-05-06 | 2016-05-06 | Humanized anti-il-1r3 antibodies |
| PCT/EP2017/060925 WO2017191325A1 (en) | 2016-05-06 | 2017-05-08 | Humanized anti-il-1r3 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018013517A true MX2018013517A (en) | 2019-07-08 |
Family
ID=55919721
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013517A MX2018013517A (en) | 2016-05-06 | 2017-05-08 | Humanized anti-il-1r3 antibodies. |
| MX2023002554A MX2023002554A (en) | 2016-05-06 | 2018-11-05 | Humanized anti-il-1r3 antibodies. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002554A MX2023002554A (en) | 2016-05-06 | 2018-11-05 | Humanized anti-il-1r3 antibodies. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11203642B2 (en) |
| EP (2) | EP3241845A1 (en) |
| JP (2) | JP7038462B2 (en) |
| KR (3) | KR102381257B1 (en) |
| CN (3) | CN116178549A (en) |
| AU (1) | AU2017260399B2 (en) |
| BR (1) | BR112018072681A8 (en) |
| CA (1) | CA3022657A1 (en) |
| EA (1) | EA201892541A1 (en) |
| IL (2) | IL297527A (en) |
| MX (2) | MX2018013517A (en) |
| NZ (1) | NZ748130A (en) |
| SG (1) | SG11201809764XA (en) |
| WO (1) | WO2017191325A1 (en) |
| ZA (1) | ZA201807167B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3055256A1 (en) | 2017-03-09 | 2018-09-13 | Mab Discovery Gmbh | Antibodies specifically binding to human il-1r7 |
| EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
| WO2018231827A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| TW202021618A (en) | 2018-08-17 | 2020-06-16 | 美商２３與我有限公司 | Anti-il1rap antibodies and methods of use thereof |
| MX2023002901A (en) * | 2020-09-14 | 2023-06-01 | Ichnos Sciences SA | Antibodies that bind to il1rap and uses thereof. |
| CN117062836A (en) * | 2021-02-05 | 2023-11-14 | 勃林格殷格翰国际有限公司 | anti-IL 1RAP antibodies |
| EP4341290A1 (en) | 2021-05-21 | 2024-03-27 | LEO Pharma A/S | Anti il-1 receptor accessory protein antibodies |
| WO2024062074A1 (en) | 2022-09-21 | 2024-03-28 | Sanofi Biotechnology | Humanized anti-il-1r3 antibody and methods of use |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5283179A (en) | 1990-09-10 | 1994-02-01 | Promega Corporation | Luciferase assay method |
| EP0488470B1 (en) | 1990-11-26 | 1997-05-28 | Akzo Nobel N.V. | Method for the production of antibodies |
| PE64396A1 (en) | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | INTERLEUKIN 1 RECEIVER ACCESSORY PROTEIN |
| US6974682B1 (en) | 1996-08-26 | 2005-12-13 | Human Genome Sciences, Inc. | Soluble interleukin-1 receptor accessory molecule |
| EP0915987A2 (en) | 1997-04-21 | 1999-05-19 | Donlar Corporation | POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE |
| US6280955B1 (en) | 1997-12-16 | 2001-08-28 | Tularik Inc. | Interleukin-1 receptor accessory proteins, nucleic acids and methods |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| US6541225B1 (en) | 2000-01-26 | 2003-04-01 | Raven Biotechnologies, Inc. | Methods and compositions for generating human monoclonal antibodies |
| US7449443B2 (en) | 2000-03-23 | 2008-11-11 | California Institute Of Technology | Method for stabilization of proteins using non-natural amino acids |
| US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
| US20030026806A1 (en) | 2000-10-27 | 2003-02-06 | Amgen Inc. | Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof |
| AU2002253842A1 (en) | 2000-10-31 | 2002-08-28 | Immunex Corporation | Il-1 receptor accessory protein |
| PL374118A1 (en) | 2001-08-07 | 2005-10-03 | Immunex Corporation | Interleukin-1 receptors in the treatment of diseases |
| WO2003073238A2 (en) | 2002-02-27 | 2003-09-04 | California Institute Of Technology | Computational method for designing enzymes for incorporation of amino acid analogs into proteins |
| NZ593428A (en) | 2002-09-06 | 2013-01-25 | Amgen Inc | Therapeutic human anti-il-1r1 monoclonal antibody |
| JP5425365B2 (en) | 2003-01-22 | 2014-02-26 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | Fusion constructs and their use for generating antibodies with increased Fc receptor binding affinity and effector function |
| US20040224893A1 (en) | 2003-05-06 | 2004-11-11 | Li-Hsien Wang | Methods of using IL-1 antagonists to treat neointimal hyperplasia |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| ES2737837T3 (en) | 2003-10-09 | 2020-01-16 | Ambrx Inc | Polymeric derivatives |
| CN102373214B (en) | 2003-11-05 | 2014-07-09 | 罗氏格黎卡特股份公司 | Antigen binding molecules with increased fc receptor binding affinity and effector function |
| EP1718602A4 (en) | 2004-01-30 | 2007-12-12 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
| CA2553040A1 (en) | 2004-02-02 | 2005-08-18 | Ambrx, Inc. | Modified human four helical bundle polypeptides and their uses |
| US8945857B2 (en) | 2005-07-01 | 2015-02-03 | John Schrader | Methods of isolating cells and generating monoclonal antibodies |
| CN101291954B (en) | 2005-08-26 | 2013-03-27 | 罗氏格黎卡特股份公司 | Modified antigen binding molecules with altered cell signaling activity |
| AU2007307324B2 (en) | 2006-05-19 | 2013-08-15 | Alder Biopharmaceuticals, Inc. | Culture method for obtaining a clonal population of antigen-specific B cells |
| EP2271673B1 (en) | 2008-03-26 | 2016-02-24 | Cellerant Therapeutics, Inc. | Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof |
| KR20150036824A (en) | 2009-03-20 | 2015-04-07 | 제넨테크, 인크. | Bispecific anti-her antibodies |
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| WO2011124718A1 (en) | 2010-04-09 | 2011-10-13 | Novozymes A/S | Albumin derivatives and variants |
| EP2400298B1 (en) | 2010-05-28 | 2013-08-14 | F.Hoffmann-La Roche Ag | Single B-cell cultivation method and specific antibody production |
| EP3508498A1 (en) | 2011-01-19 | 2019-07-10 | Cantargia AB | Novel agents and uses thereof |
| WO2012142391A1 (en) | 2011-04-15 | 2012-10-18 | Merck Patemt Gmbh | Anti- il-1r1 inhibitors for use in cancer |
| CN103608030A (en) * | 2011-06-21 | 2014-02-26 | 昂科发克特公司 | Compositions and methods for therapy and diagnosis of cancer |
| US9873918B2 (en) | 2011-08-11 | 2018-01-23 | Albert Einstein College Of Medicine, Inc. | Treatment of acute myeloid leukemia and myelodysplastic syndromes |
| WO2014100772A1 (en) | 2012-12-21 | 2014-06-26 | Cellerant Therapeutics, Inc. | Antibodies that bind membrane-bound il1rap |
| WO2014113433A1 (en) | 2013-01-16 | 2014-07-24 | George Mason University | Binding domain mapping |
| GB201403875D0 (en) * | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| GB201413913D0 (en) * | 2014-08-06 | 2014-09-17 | Cantargia Ab | Novel antibodies and uses thereof |
| EP3960765A1 (en) | 2015-06-26 | 2022-03-02 | Sanofi Biotechnology SAS | Monoclonal anti-il-1racp antibodies |
| EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
-
2016
- 2016-05-06 EP EP16168617.5A patent/EP3241845A1/en not_active Withdrawn
-
2017
- 2017-05-08 KR KR1020187034930A patent/KR102381257B1/en active IP Right Grant
- 2017-05-08 JP JP2019510473A patent/JP7038462B2/en active Active
- 2017-05-08 CN CN202211533431.5A patent/CN116178549A/en active Pending
- 2017-05-08 EA EA201892541A patent/EA201892541A1/en unknown
- 2017-05-08 MX MX2018013517A patent/MX2018013517A/en unknown
- 2017-05-08 AU AU2017260399A patent/AU2017260399B2/en active Active
- 2017-05-08 KR KR1020237021882A patent/KR20230107695A/en not_active Application Discontinuation
- 2017-05-08 CN CN201780041725.7A patent/CN109415442B/en active Active
- 2017-05-08 NZ NZ748130A patent/NZ748130A/en unknown
- 2017-05-08 BR BR112018072681A patent/BR112018072681A8/en unknown
- 2017-05-08 IL IL297527A patent/IL297527A/en unknown
- 2017-05-08 IL IL262776A patent/IL262776B2/en unknown
- 2017-05-08 WO PCT/EP2017/060925 patent/WO2017191325A1/en active Application Filing
- 2017-05-08 SG SG11201809764XA patent/SG11201809764XA/en unknown
- 2017-05-08 US US16/099,059 patent/US11203642B2/en active Active
- 2017-05-08 CN CN202211533197.6A patent/CN116178548A/en active Pending
- 2017-05-08 EP EP17724778.0A patent/EP3452513B1/en active Active
- 2017-05-08 KR KR1020227010275A patent/KR102550643B1/en active IP Right Grant
- 2017-05-08 CA CA3022657A patent/CA3022657A1/en active Pending
-
2018
- 2018-10-26 ZA ZA2018/07167A patent/ZA201807167B/en unknown
- 2018-11-05 MX MX2023002554A patent/MX2023002554A/en unknown
-
2022
- 2022-03-03 JP JP2022032317A patent/JP7480199B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023002554A (en) | Humanized anti-il-1r3 antibodies. | |
| MX2022004072A (en) | Factor xi antibodies and methods of use. | |
| MY196224A (en) | Human Antibodies To Ebola Virus Glycoprotein | |
| PH12015500084A1 (en) | Rspo3 binding agents and uses thereof | |
| PH12018500174A1 (en) | Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer | |
| MX360671B (en) | Pharmaceutical composition for treatment and/or prevention of cancer. | |
| MX349198B (en) | Rspo binding agents and uses thereof. | |
| MX2018010331A (en) | Vegf/dll4 binding agents and uses thereof. | |
| EA201490957A1 (en) | TREATMENT OF HEMATOLOGICAL MALIGNANT DISEASES WITH ANTI-CXCR4 ANTIBODY | |
| MX2018010672A (en) | Antibodies to cd40 with enhanced agonist activity. | |
| NZ629828A (en) | Methods for the treatment of b cell-mediated inflammatory diseases | |
| EP3991749A3 (en) | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody | |
| BR112016023011A2 (en) | gastric cancer treatment | |
| ZA201907754B (en) | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer | |
| MX2020011377A (en) | Methods and compositions for treating chronic urticaria. | |
| PH12018501674A1 (en) | Anti-citrullinated hla polypeptide antibodies and uses thereof | |
| BR112022001037A2 (en) | Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agents | |
| MX2022003762A (en) | Binding molecule specific for lif and use thereof. | |
| MX2022006941A (en) | Trpv1 epitopes and antibodies. | |
| MX2017001983A (en) | Rspo1 binding agents and uses thereof. | |
| MX2021012406A (en) | Combinations of anti-ildr2 antibodies and pd-1 antagonists. | |
| EA202092481A1 (en) | COMBINED TREATMENT WITH CD73 ANTAGONIST AND PD-1 / PD-L1 AXIS ANTAGONIST | |
| MX2020002813A (en) | Use of il-1b binding antibodies for the treatment of alcoholic hepatitis. | |
| EA202092640A1 (en) | METHODS AND COMPOSITIONS FOR TREATMENT OF CHRONIC urticaria | |
| EA201892069A1 (en) | METHODS OF TREATMENT OR PREVENTION OF THE DISEASE "TRANSPLANTAT AGAINST THE OWNER" |